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Introduction: Studies of preclinical models are essential for
determining the biology of lung cancers and testing new
and novel therapeutic approaches. We review the
commonly used preclinical models for lung cancers and
evaluate their strengths and weaknesses.
Methods: We searched the MEDLINE database via PubMed
using combinations of the following medical subject head-
ings: lung cancer; animal models, mice; cell line, tumor; cell
culture, mice; transgenic, mice; SCID, transplantation; het-
erologous; and genetic engineering. We reviewed the rele-
vant published articles.
Results: Multiple examples of the three major preclinical
models—tumor cell lines, patient-derived xenografts, and
genetically engineered mouse models—exist and have
been used by investigators worldwide, with more than
15,000 relevant publications. Each model has its
strengths and actual or potential weaknesses. In addition,
newer forms of these models have been proposed or are
in use as potential improvements over the conventional
models.
Conclusions: A large number and variety of models have
been developed and extensively used for the study of all
major types of lung cancer. While they remain the corner-
stone of preclinical studies, each model has its individual
strengths and weaknesses. These must be carefully evalu-
ated and applied to the proposed studies to obtain the
maximum usefulness from the models.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Cell lines; Genetically engineered mouse models;
Lung cancer; Patient-derived xenografts; Cell lines; Pre-
clinical models; Neuroendocrine carcinomas; Non–small
cell lung cancer; Small cell lung cancerIntroduction
Preclinical models for cancers, including lung can-
cer, are crucial for understanding biology and for the
development and testing of conventional and novel
therapeutic agents. Comprehensive reviews of all of the
three basic methods that form the pillars of preclinical
models have been recently published: cell cultures,
patient-derived xenografts (PDXs), and genetically
engineered mouse models (GEMMs). However, to the
best of our knowledge, no comprehensive review of the
entire subject has been published, although murine
models were well covered in a recent review.1 Our aim
was to provide such a review of preclinical models for
lung cancers. In addition, we discuss some recent novel
approaches to potentially improve the basic models.Journal of Thoracic Oncology Vol. 11 No. 3: 287-299
Table 2. Strengths and Limitations of Cell Lines for the
Study of Lung Cancer
Strengths Limitations
Maintain cytological appearances
and differentiated cell
properties
May represent oligoclonal
selection and demonstrate
genetic drift on prolonged
passage
Retain driver oncogenes Lack of stroma and
vasculature may limit use
for immunotherapy or
vasculature targeting
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and we therefore discuss the advantages and disad-
vantages of each model. Because this review encom-
passes multiple models, we cannot cover each model in
as much detail as do reviews of individual models.
However, by giving an overall review of the major
models, a clearer picture of the ﬁeld and the
interrelationships and uses of the different models
can be obtained.
Because small cell lung cancer (SCLC) tumors are
seldom resected, only sparse diagnostic materials are
occasionally available for the study of biology and for the
development and testing of innovative therapeutic ap-
proaches. In vitro models to study this “recalcitrant
disease” are therefore of crucial importance for this type
of lung cancer.
The use of these models was ﬁrst explored 30 to 40
years ago. Recently, new approaches have been pro-
posed or implemented that may alter and improve our
approach to the study of such models, and these are
summarized at the end of this review. The major
strengths and limitations of these three basic preclinical
model systems are summarized below. The current
models, especially for GEMMs, represent major im-
provements and innovations over the earlier systems.
We focus on the more recent models and also discuss
newer concepts that may improve or alter our present
models. We do not discuss the sparsely studied syn-
geneic and spontaneous mouse models. The three
models allow for experimental tests of various thera-
peutic approaches and the role(s) of various genetic
and epigenetic changes in lung cancer pathogenesis and
biology and the study of tumor heterogeneity and stem
cells.Useful for in vitro
experimentation, drug
screening, and testing of
targeted gene therapies
More controversial for
testing conventional
therapies
Relatively inexpensive,
technically simple and
availability for widespread
distribution
Nonmalignant counterpart
for peripheral airway
adenocarcinomas or SCLC
(cultured pulmonary NE
cells) not available.
Maintain cytological appearances
and differentiated cell
Most cell lines are grown as
two-dimensional cultures;Methods
We searched the MEDLINE database via PubMed
using combinations of the medical subject headings
(MeSH) terms as described in Table 1. In this review, we
focus on and frequently cite review articles because they
give a broad overview of their respective topics and
reduce the number of cited references.Table 1. Citations to Preclinical Models for Lung Cancer
MeSH Terms Used for MEDLINE Search No. of Citations
Cell line, tumor and human 11,705
Mice, SCID or mice nude 3223
Animals and models, genetic 923
Totals 15,851
A MEDLINE search was conducted via PubMed on September 16,
2015 using the MeSH term lung neoplasms and the other MeSH
terms as indicated.Results
A recent (September 18, 2015) search of the MED-
LINE database using the major MeSH terms carcinoma,
pulmonary, and other terms as indicated in Table 1
yielded more than 15,800 citations, with the majority
of them referring to lung cancer tumor cell lines. How-
ever, the other two major models were also well repre-
sented. All of the three “pillars” of the preclinical models
for lung cancer are well used and cited.Tumor Cell Lines
However, the relevance of cancer cell lines has
remained controversial for many reasons beyond the
scope of this article. Three recent articles have
addressed these issues and indicated that carefully
characterized cell lines are highly relevant for many but
not all studies, and must be evaluated for the speciﬁc
purpose for which they were used.2–4 The pros and cons
of cell lines are discussed in Table 2. Some of the same
statements apply to all of the in vitro models. Of interest,
a recent study found that newly established ovarianproperties ability to transfer to a
three-dimensional model
may ability to differentiate
and relevance of drug testing
Can be cryopreserved at early
passage before the
development of secondary
genetic changes
Immortalized respiratory
epithelial cells available for
use as nonmalignant
counterparts
NE, neuroendocrine; SCLC, small cell lung cancer.
March 2016 Preclinical Model Systems for Study of Lung Cancers 289cancer cell lines faithfully reproduced the properties of
their human tumor counterparts.5
Permanent lung cancer cell cultures were established
in the 1970s. The ﬁrst SCLC line was established in
19716 (although reported in 1973), precisely 20 years
after George Gey established HeLa, the world’s ﬁrst
continuous human tumor cell line.7 Of interest, Gey also
grew strains of lung adenocarcinomas,8 but apparently
these could not be maintained as permanent cell lines.
Compared to other types of human carcinomas, the
number of lung cancer lines is much larger,2 and their
study by hundreds of investigators worldwide has
formed the basis of much of our knowledge of the
biology of this disease, and, as previously noted, has
generated many thousands of published reports.2 We
maintain a database of the NCI-H and HCC series (initi-
ated by A.F.G. and J.D.M.) and other readily available or
cited lung cancer cell lines (N ¼ 431; SCLC ¼ 172, non–
SCLC ¼ 259). Of those with known ethnicities, 84% are
of white or Hispanic origin, 14% are of African American
origin, and 2% are of East Asian origin. While the recent
literature, in particular, cites many lung cancer lines
initiated in Asian countries, unfortunately most of these
are not readily available in Western countries. The
epidermal growth factor receptor (EGFR) mutant PC9
line is most frequently cited (149 citations). Much
additional information about the cell lines is available
from public databases.
Some of the most important ﬁndings regarding
biology or therapeutic applications derived from the use
of cell lines are cited in Table 3. A large amount of genetic
information regarding gene expression, mutations and
copy number variations about the NCI-H and HCC series
of cell lines initiated by the authors (A.F.G. and J.D.M.) at
the following locations: (1) data from the University
of Texas Southwestern is available from the Gene Ex-
pression Omnibus (GEO) datasets maintained by the
National Center for National Center for BiotechnologyTable 3. Highlighted Discoveries Using Lung Cancer Cell
Lines
Deletions of chromosome 3p are characteristic of both SCLC and
NSCLC, and identiﬁcation of multiple tumor suppressor genes in
this region57–61
Cell lines play an important role in the discovery of the roles of
key driver oncogenes, including RB, TP53, MYC, LMYC, EGFR,
BRAF, and PIK3CA ampliﬁcation, identiﬁcation of the LMYC gene,
and identiﬁcation and understanding their roles in lung cancer
pathogenesis62–69
Role of cell lines in demonstrating efﬁcacy of targeted therapies
and the mechanisms of resistance13,70–72
Whole genome cloning of a SCLC line10
With more than 11,000 citations to human cell lines, only a few of
the important discoveries are mentioned. These show the impact
of cell lines on lung cancer pathogenesis, biology, and therapy.
NSCLC, Non–small cell lung cancer; SCLC, small cell lung cancer.Information (NCBI; http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc¼GSE32036); (2) the Cancer Cell Line
Encyclopedia (CCLE) maintained by the Broad Institute
(http://www.broadinstitute.org/ccle/data/browseData?
conversationPropagation¼begin) has copy number varia-
tion, gene expression, and mutation data; and (3) as does
the Catalogue of Somatic Mutations in Cancer (COSMIC)
maintained by the Wellcome Trust Sanger Institute
(http://cancer.sanger.ac.uk/cell_lines/download).
Examination of these databases provides an over-
view of the complexity of the mutational proﬁle of
lung cancer.9 The enormous mutational burden pre-
sent in lung cancers, primarily because of tobacco
exposure over many years, was ﬁrst demonstrated
when scientists at the Sanger Institute (in collabora-
tion with A.F.G. and J.D.M.) ﬁrst sequenced a SCLC cell
line and its corresponding B lymphoblastoid line and
found nearly 23,000 somatic substitutions.10 This
study also vividly demonstrated the importance of
having a corresponding source of constitutional DNA.
Efforts to obtain DNA from the original tumor, whether
fresh frozen or formalin ﬁxed, parafﬁn embedded
(FFPE) are also of great value in interpreting somatic
changes and the acquisition of additional changes
during prolonged culture life. It is important to cryo-
preserve a large number of vials at early culture pas-
sage and use these rather than maintain cultures for
indeﬁnite passages.
An important problem with the use of cell lines is the
absolute necessity to establish the true provenance of
the cell lines; mix-ups and misattributions remain a
major problem with numerous reports based on
spurious identiﬁcation.11 Quality control and myco-
plasma contamination are also major problems. Journal
editorial policy should require evidence of provenance
and identiﬁcation of the original and direct sources of
the cell lines used in submitted reports.
Non–Small Cell Lung Cancer Lines
NSCLC lines were ﬁrst initiated in the early 1970s
and included the widely used A549 cell line (Fig. 1).12
Currently we are aware of more than 200 cell lines,
with perhaps 120 widely distributed and used by the
scientiﬁc community. The widely distributed ones have
been extensively characterized and used,2 although some
of the information, including complete genomic
sequencing, are not yet available to the scientiﬁc public.
The cell lines are heavily biased towards adenocarci-
nomas, the most common form of lung cancer. Although
about 30 squamous cell carcinoma (SCC) cell lines have
been reported, molecular classiﬁcation indicates that
many are misattributed or are poorly differentiated
(unpublished data). Therefore, the number of bona ﬁde
well differentiated SCC lines needs to be increased. They
Figure 1. Lung cancer cell lines. (A) Non–small cell lung cancer culture HCC1897, growing as ﬂat adherent cells. (B) Small cell
lung cancer culture, triple-knockout mouse model. Both mouse and human small cell lung cancer cultures usually grow as
ﬂoating aggregates or true spheroids (as shown). The larger spheroids frequently develop necrotic or hollow centers.
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therapies for SCC are tested and translated to the clinic.
Full genomic classiﬁcation of the frequently used NSCLC
lines including molecular estimates of degree of differ-
entiation and of tobacco-induced damage will be pub-
lished by the authors in the near future.
Although the clinical relevance of in vitro drug testing
of cell lines remains controversial, genomic changes, such
as driver oncogene mutations and oncogene addiction,
are maintained. Cell lines therefore accurately reﬂect the
clinical responses to several targeted therapies, including
EGFR mutant cell line responses to tyrosine kinase in-
hibitors,13 and for crizotinib response in anaplastic
lymphoma kinase (ALK)-translocated cell lines.14 NSCLC
cell lines are useful preclinical models for evaluating
targeted therapies and for investigating methods of
therapy resistance. Because genomic changes, especially
for driver mutations, are stable, these properties have
been maintained in long cultured cell lines.
Small Cell Lung Cancer Lines
The Japanese authors who grew the world’s ﬁrst
SCLC cell line noted that it grew as ﬂoating cell aggre-
gates6 in contrast to most adherent epithelial tumor cell
cultures. Most SCLC lines grow as ﬂoating cultures
(Fig. 1), and the few that grow adherent may not have
arisen from true or typical SCLC. During the 1970s,
investigators in Japan, Dartmouth Medical School,15 and
the NCI established panels of SCLC lines.16 Because of
unique clinical resources then available at the NCI,
a large series of cell lines was established by Drs.
Gazdar, Desmond Carney, and Minna (and collabora-
tors) from both limited and extensive disease tumors,
and even, in a few cases, from extrapulmonary smallcell carcinomas.17 In addition, these lines were estab-
lished before and after the administration of cytotoxic
therapy. Most lines retained the cytologic and neuro-
endocrine (NE) cell features of SCLC tumors. A recent
unpublished characterization by the author has
conﬁrmed that a vast majority of the NCI series of lines
has retained these features even after 4 decades in
culture. Some of the lines, especially those established
after previous therapy and that had ampliﬁcation of a
MYC family gene, had atypical morphology and lacked
some of the NE cell program. These were termed
variant SCLC cell lines.18 The NCI series were deposited
in the American Type Culture Collection and widely
distributed to investigators worldwide. Because of the
difﬁculty in obtaining human SCLC tumor materials,
they remain the major resource for most of the bio-
logical studies performed in SCLC.2 Constitutional
sources of DNA (primarily B lymphoblastoid cell lines)
are available for some of the lines. A major shortcoming
is a lack of cell lines established from the putative
precursor cell, the NE cells of the respiratory
epithelium.
While they are an estimated 150 SCLC tumor cell
lines (TCLs) established worldwide, recent reports have
been scarce. Two recent developments, discussed later,
offer innovative new approaches to the establishment of
SCLC cancer lines.
Patient-Derived Xenografts
PDX tumors are generated by the direct transfer of
human tumor fragments or cell isolates from patient
tumors to immunodeﬁcient mice (or other rodent spe-
cies). Established TCLs may also be used as a source of
xenografts, although they may represent a narrow range
March 2016 Preclinical Model Systems for Study of Lung Cancers 291of subpopulations resulting from the “double” selection
(i.e., during cell culture and xenograft growth). A partial
list of some of the cell line xenografts has been pub-
lished.1 While PDXs were established more than 40 years
ago,19 the variety of immunodeﬁcient rodent strains has
increased considerably, with increased engraftment
rates, although at considerably increased costs. As dis-
cussed below and in Table 4, PDXs may represent
improved models for drug discovery and validation, have
been used for biomarker discovery and validation, can
provide relatively large numbers of tumor cells for a host
of biological and other studies, and can be used to
establish cell lines. In fact, when A.F.G. and J.D.M. were
ﬁrst attempting to establish SCLC cultures in the 1970s,
initial efforts from human tumors failed while PDX cul-
tures provided their ﬁrst successful long-term cell lines.
We are also currently using PDXs to boost the sparse
number of well characterized human SCC cultures
available worldwide. However, we have noticed that
variable numbers of mouse stromal cells may persist in
PDX-derived cell lines for many years, and monitoring of
the mouse:human cell ratio is important. In fact we, and
others, have noted that some “PDXs” consist entirely of
mouse-derived sarcomalike tumorigenic cells.
Primary or metastatic tumors may be used, as can
malignant effusions. Sometimes the tumor cells are
admixed with Matrigel or mesenchymal cells in efforts toTable 4. Strengths and Limitations of Patient-Derived
Xenografts for the Study of Lung Cancer
Strengths Limitations
Histology and gene expression
proﬁle of tumors more
closely resembles human
pathology and may be more
reﬂective of human
counterpart, especially for
testing and selection of
conventional and targeted
therapies
Most common site of
propagation (subcutaneous)
not representative of
human counterpart
Useful for in vitro
experimentation, drug
screening, and testing of
targeted gene therapies
After passage, stroma and
vasculature are of host
mouse origin
“Mouse avatars” may help
identify drugs for
individualized therapies
Lack of immune system
prevents immunotherapy
targeting
Metastatic spread is rare and
does not resemble human
counterpart
Difﬁcult to genetically
manipulate
May be contaminated with
murine xenotropic virus
Large representative model
sets not readily available
and expensiveincrease engraftment rates. In general, the more severe
the immunodeﬁciency of the mouse host, the greater
the take rates, and non-obese diabetic/sever combined
immunodeﬁciency (NOD/SCID) or NOD/SCID/gamma
(NSG) mice are preferable but more expensive. While the
usual route of inoculation is subcutaneous in the dorsal
region, orthotopic models for SCLC may increase meta-
static potential and relevance for chemotherapy evalua-
tion.20 However, because the usual reason for death from
lung cancer is metastatic spread, this view is not uni-
versally held. Intracranial heterotransplantation of SCLC
into the brain provides a model to study intracranial and
leptomeningeal meatastases.21 Inoculation into vascular
sites, such as the subrenal capsule, may also increase
take rates. One of the major advantages of the subcu-
taneous route is the ease of monitoring tumor growth.
At least during early serial passage, PDXs retain the
genetic and morphologic characteristics of the original
human tumor, including histologic features, gene
expression proﬁles, copy number variations, and chro-
mosomal stability of PDX tumors (see Fig. 2 and
Table 4).19 In one recent study, the success rate for
establishing PDXs from resected NSCLC was approxi-
mately 50%,22 although most studies report lower rates.
More than 90% of the mutations identiﬁed in the pri-
mary tumors were also present in the corresponding
PDXs. However, additional unique mutations were
detected in the PDXs, suggesting genetic drift or het-
erogeneity in the original tumors. Potential shortcomings
of PDX models include the gradual replacement of
patient-derived stroma with mouse-derived stroma, the
lack of an intact immune system, the lack of metastatic
spread in most models, and frequent engraftment in an
unnatural (subcutaneous) setting. Another potential
problem—contamination of the engrafted human cells
with mouse xenotropic virus—is discussed below.
With the heightened interest in PDXs,23,24 especially
for the testing of conventional and targeted therapies, it
is important to establish large banks of different tumor
types in order to capture the genetic diversity and het-
erogeneity of human tumors and the range of drug
sensitivities. Because of the cost and effort of establish-
ing such banks, they are best performed by consortiums
that pool resources and make them available to the sci-
entiﬁc public. One such effort is by the newly established
European EurOPDX initiative.25
The mouse genome contains more than 500,000
copies of integrated strains of the mouse leukemia virus.
Some strains are xenotropic and grow efﬁciently in hu-
man cells. Serial transplantation of PDXs, especially
SCLC, is associated with a high frequency of xenotropic
virus contamination,27 which poses potential health risks
and may inﬂuence genetic, immune, and metabolic ana-
lyses. Unfortunately, the tumors themselves cannot be
Figure 2. Patient-derived xenografts of moderately differentiated squamous cell carcinoma. The histological appearances of
the patient-derived xenografts are similar to those of the original lung cancer.
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because the PDXs contain mouse-derived cells with
numerous copies of the integrated genomes. The only
method currently available is for culture of the PDXs and
to test for virus release into the supernatant ﬂuids.
Paradoxically, the mouse cells release low or absent
levels of the virus, while the infected human cells release
enormous amounts.27
Genetically Engineered Mouse Models
Earlier studies of mouse models focused on exposure
to chemical carcinogens, including smoke exposure, and
even on skin painting. However, most involved systemic
or intratracheal administration of the carcinogen. These
studies have been summarized recently, and are not
discussed further.28
More comprehensive reviews of lung cancer GEMMs
have been published,29–31 and only certain aspects are
highlighted in this report. We start with a brief explana-
tion of some of the important terms and techniques.
The following deﬁnitions are taken from the Jackson
Laboratory website (available at research.jax.org/grs/
type/gemm/): genetically engineered mice have induced
mutations, including transgenes, targeted mutations (i.e.,
knockouts or knockins), and retroviral- or proviral-
induced mutations. Transgenic mice carry a segment of
foreign DNA incorporated into their genome via nonho-
mologous recombination (e.g., pronuclear microinjec-
tion), infection with a retroviral vector, or homologous
insertion. Targeted mutant mice are produced by ﬁrst
inducing gene disruptions, replacements, or duplications
into embryonic stem (ES) cells via homologous recom-
bination between the exogenous (targeting) DNA and the
endogenous (target) gene. The genetically modiﬁed ES
cells are then microinjected into host embryos at the
eight-cell blastocyst stage. These embryos are trans-
ferred to pseudopregnant host females, which then bearchimeric progeny. The chimeric progeny carrying the
targeted mutation in their germline are then bred to
establish a line. If the newly established line has a dis-
rupted or deleted gene, it is called a knockout; if it has a
new or duplicated gene, it is called a knockin. Genetically
modiﬁed mice are used extensively for in vitro studies,
especially the knockout mouse, where the activity of one
or more genes has been removed. Such models are of
crucial importance in understanding the role that newly
discovered lung cancer genes play in tumorigenesis and
for distinguishing passenger from driver oncogenes.
They also play pivotal roles in understanding multistage
pathogenesis, the identiﬁcation of tumor biomarkers, the
development and testing of newer therapeutic ap-
proaches, and for the understanding and overcoming of
drug resistance (Table 5). We have the capacity to swiftly
reengineer complex genetic lesions present in lung can-
cers, which allows us to study of the interplay between
deﬁned genetic combinations tumor formation and
metastasis. As such, they are invaluable complements to
cell culture systems, especially for studies requiring
intact, immunocompetent animals. One example of an
applied, clinically relevant application used multiple
mouse models to identify blood proteomic signatures for
lung adenocarcinoma (ADC) and neuroendocrine (NE)
carcinomas.32
GEMMs for ADCs of the Lung. More GEMMs exist for
ADC than for the other histologic types.31 The most
common models generated are for Kras or Egfr activa-
tion, but multiple other models involve Braf, Her2, Eml-
Alk, Pik3ca, or other genes (Fig. 3).31 Conditional models,
as for Egfr, may show complete tumor responses after
removal of the driver gene, a dramatic demonstration of
oncogene addiction. GEMMs for ADC are often stated to
be suitable models for the study of peripherally arising
cancers that faithfully reproduce the steps of human
Table 5. Strengths and Limitations of Genetically
Engineered Mouse Models for the Study of Lung Cancer
Strengths Weaknesses
Tumors develop after
multistage pathogenesis
Rapid development of ADC
models often results in death
before tumor formation
Tumor morphology often
resembles human
counterpart
Preneoplastic stages of ADC do
not mimic human counterpart
For NE carcinomas, pattern of
metastatic disease closely
resembles that of human
SCLC
Relatively long latent time for
NE carcinomas and precise
histology or histological
mixture dependent on many
variables, necessitating
detailed pathological
examination
Only model currently
available for the study
of preneoplastic and
preinvasive lesions of lung
NE carcinomas
Lack of tobacco exposure results
in tumors having lower
mutational burdens than
human counterparts and
altered genomic signature
Useful for dissecting role of
individual genes and gene
interactions as well as
oncogene addiction
Relatively easy to genetically
model; complex models
can be generated relatively
quickly
Useful for studying and
developing novel therapies
and drug resistance
ADC, Adenocarcinoma; NE, neuroendocrine; SCLC, small cell lung
cancer.
Figure 3. Typical Kras-driven genetically engineered mouse
model for lung adenocarcinoma. The most striking feature is
the massive alveolar cell hyperplasia. If the mice do not die
of respiratory failure, adenomas may develop that progress
to adenomas with dysplasia, adenocarcinoma in situ, and
invasive carcinoma. Courtesy of James Kim, MD, PhD.
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thologists, there are some similarities and many differ-
ences. Most ADC GEMMs result in rapid and generalized
hyperplasia of type 2 cells. This is said to resemble
atypical adenomatous hyperplasia (AAH), an early pre-
neoplastic stage in human lung cancer.33 However, AAH
lesions are usually discrete and small, with some degree
of interalveolar ﬁbrosis, not generalized lesions
involving much of the peripheral lung. The type 2 hy-
perplasia of ADC GEMMs may cause death or elective
sacriﬁce from respiratory distress before the lesions can
progress. Mice that survive may develop adenoma for-
mation, a minority of which may develop dysplasia and
even later, invasive or metastatic carcinomas. However,
most mice die before tumors can develop. Adenoma
formation is not part of human multistage pathogenesis.
GEMMs for ADC have the least resemblance to the
development of the human counterpart compared to
GEMMs for SCC or NE carcinomas (see below). These
differences do not diminish the overall importance of
these models, and GEMMs for Egfr and Eml-Alk are
excellent models to study therapies targeted toward
these drivers.It is becoming clear that KRAS-driven lung cancers
are not a single homogenous entity,34 and ﬁndings from
GEMMs conﬁrm these observations in human subjects.35
Of great interest is the fact that chemical carcinogen–
induced models and GEMMs may result in identical Kras-
activating mutations, although they have different sig-
natures and secondary alterations.35 Carcinogen models
may therefore play a role in understanding the multiple
pathogenic pathways resulting from activation of a single
oncogene.
GEMMs for NE Carcinomas of the Lung. A decade ago,
Berns et al.36 developed a GEMM for SCLC based on the
ﬁnding that p53 and Rb1 were almost always inacti-
vated in patients with SCLC. This double-knockout
model closely recapitulated the histology and metasta-
tic pattern of SCLC but had a relatively long latent
period. Several triple-knockout variants of the basic
model have been developed, speciﬁcally to reduce the
long latent period, as recently reviewed (Fig. 4).37
However, these variations often have more complex
histologies, reﬂecting the spectrum of high-grade NE
carcinoma of the lung. The resultant histological phe-
notypes were inﬂuenced by the introduction of speciﬁc
genetic alterations, by inactivation of one or both alleles
of speciﬁc genes, by time from Cre activation, and by
targeting of lung epithelial cells in general or speciﬁc
targeting of NE cell subpopulations. The lengthy latent
time permitted observations of the preneoplastic and
premalignant stages of SCLC development, which are
seldom observed in human tumors because of the
explosive growth of SCLC once it becomes invasive. The
long latent period is caused by the development of
Figure 4. Genetically engineered triple-knockout mouse models for neuroendocrine lung cancers. (A) Early central lesion
arising in a large bronchus. Both the in situ and invasive components are characteristic of large cell neuroendocrine carci-
noma (LCNEC) with pseudoglandular formation. (B) Massive mediastinal spread of the small cell lung carcinoma (SCLC)
component, even though corresponding intrapulmonary tumors are relatively small. (C) Mixed tumor with LCNEC (left) and
SCLC (on right) components blending into each other. (D) Liver metastases with SCLC elements only, even though the primary
tumor had both SCLC and LCNEC components. The SCLC component predominated in metastatic lesions, regardless of the
histology of the corresponding lung tumors. (Reprinted from Gazdar et al.,37 with permission.)
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tion, such as alterations of the PTEN and NFIB genes.38
A recent review37 concluded that GEMM models studied
are representative for the entire spectrum of human
high-grade NE carcinomas, including SCLC, large cell
neuroendocrine carcinomas (LCNEC), NSCLC with NE
cell properties (NSCLC-NE), and are also useful for the
study of multistage pathogenesis and the metastatic
properties of these tumors. In some of the triple-
knockout models, the LCNEC component was more
dominant than the SCLC component. It also appeared as
if these two components demonstrated plasticity and
could alter from one to the other and were often closely
intermixed. At early time points, in situ lesions or in situ
lesions with an invasive component can be observed.
Because of the explosive growth of SCLC, and because
SCLC tumors are seldom resected, preneoplastic and
preinvasive lesions are seldom, if ever, observed in
human tumors. GEMMs for NE carcinomas therefore
provide the only opportunity to study the multistage
pathogenesis of SCLC and other high-grade NE carci-
nomas of the lung. Unlike GEMMs for NSCLC, explosive,
widespread metastases often develop relatively early inthe course of NE carcinoma GEMM development and
mimic the patterns seen in SCLC (i.e., extensive vascular
and lymphatic invasion, massive mediastinal nodal
spread, and multiple gross and microscopic hepatic
metastases).37 Of interest, in tumors consisting of mixed
SCLC and LCNEC histologies, the SCLC component was
usually the predominant or sole histology in metastases,
indicating that SCLC has more metastatic potential than
LCNEC. They represent one of the most advanced forms
of currently available GEMM models for the study of
human cancer.37
GEMMs for SCC of the Lung. There are relatively few
mouse models for SCC. This may reﬂect the fact that
there are no squamous cells in the normal respiratory
epithelium, and SCC presumably arises from metaplastic
squamous cells that appear after chronic irritation from
exposure to cigarette smoke or other reasons, including
chronic inﬂammation, which is often a prominent feature
in the lungs of smokers.
The metaplastic epithelium may then be subjected to
progressive preneoplastic and preinvasive steps, ending
in invasive SCC. These steps include squamous dysplasia
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Lung chemoprevention trials have been largely per-
formed using squamous dysplasia as an endpoint, and
mouse models are important for chemoprevention
studies and for the development and testing of novel
therapies for SCC. The cancers in these models arise after
following the same multistage pathogenesis steps that
precede the onset of human SCC.
Chemically induced and GEMM models for SCC
exist.39 Three GEMM models for SCC also have recently
been described. An important feature of the GEMM
models for SCC is that they appear to follow a similar
multistage pathogenesis as do human SCC. Simultaneous
inactivation of Stk1 (Lkb1) and activation of mutant Kras
result in a spectrum of histological types, including SCC,
and have been used for chemoprevention studies.39 The
shortcoming of this model is that Lkb1 and Kras inacti-
vation are features more closely associated with ADC,
and the mixture of the resultant tumor histologies.
Another recent report found that kinase dead Ikka
knockin mice develop spontaneous SCC with down-
regulation of Ikka and marked pulmonary inﬂamma-
tion.40 Ikka is an integral component of Ikk that is
required for the maturation of squamous cells and may
play a role in tumor development. A third recent report
found that loss of Lkb1 and Pten leads to purely SCC
tumors with features of bronchial basal cells and other
characteristics of human SCC.41 Of interest, the resultant
tumors had elevated programmed death-ligand 1
expression. Programmed death-ligand 1 expression is
believed to facilitate the escape of tumor cells from im-
mune surveillance and is currently the intense focus of
several clinical lung cancer trials.
Some Recent Applications for Preclinical Lung
Cancer Models
Conditionally Reprogrammed Cells. Schlegel et al.42
recently described the “Georgetown method” for the
propagation of epithelial cells of nonmalignant and
malignant origin. The resultant conditionally reprog-
rammed cells (CRCs) had properties of epithelial stem
cells. The success rates, even from small numbers of
cells, were high. The method used an irradiated mouse
3T3 cell feed layer and the addition of a RHO kinase
(ROCK) inhibitor. The irradiated cells provided growth
factors while the ROCK inhibitor had multiple functions,
including suppression of CDKN2A. These ﬁndings were
widely used to generate many new putative lung cancer
TCLs, mainly of NSCLC origin, by multiple laboratories.
Our extensive characterization (Boning Gao, A.F.G. and
J.D.M., unpublished data) of CRCs established from
NSCLC specimens indicated robust growth of epithelial
cells that were apparently free of ﬁbroblast contami-
nation. However, characterization of the cells indicatedthat they mostly had properties of respiratory epithelial
basal stem cells derived from nonmalignant cells and
were diploid and lacked mutations present in the cor-
responding tumors. However, some specimens con-
tained a minority of tumor cells. These results suggest—
at least for lung cancer specimens—that the CRC
method preferentially grows the nonmalignant epithe-
lial stem cell component present in all lung cancer
resections.
Using a modiﬁcation of the original CRC method—
substituting human feeder layer cells for mouse and
using recurrent tumors, primarily metastatic—a recent
report claimed to have established several lung cancer
cell lines that retained the original mutations present in
the tumors.36 However, it is was not possible to deter-
mine from the report whether the resultant cell lines
consisted of tumor cells or mixtures of tumor and
nonmalignant cells.
Circulating Tumor Cells: A New Source for PDX
Formation. As previously discussed, SCLC tumor ma-
terials are difﬁcult to obtain for laboratory studies. It
has been known for some time that SCLC is associated
with high numbers of circulating tumor cells (CTCs). A
resourceful study demonstrated that CTCs from pa-
tients with SCLC could be used to form PDXs in
immunocompromised mice (termed CDXs), and that the
resultant CDXs mirrored the donor patient’s response
to platinum and etoposide chemotherapy.43 Genomic
analysis of isolated CTCs revealed considerable simi-
larity to the corresponding CDX. These unique mouse
models provide systems for therapy testing and for
understanding drug resistance mechanisms. It remains
to be determined if TCLs can be obtained from CTCs or
whether CDXs could be used as a source for establish-
ing new cell lines.
Are Three Better Than Two (Dimensions)? Several
recent reports have suggested that three-dimensional
in vitro growth more closely resembles the natural
growth characteristics of patient tumors and may be
more representative of drug response.44 Unlike two-
dimensional cultures, spheroid or three-dimentional
cultures may maintain polarity, differentiation, are
enriched for stem cells, and more closely resemble
glandular organs.45 Additional advantages include
nonuniform exposure to drugs/compounds, oxygen and
nutrients, extracellular matrix-to-cell signaling, prolifer-
ation gradients, paracrine signaling, and increased cell–
cell interactions.46 Both cell lines and tumors may be
adapted to spheroid culture, as has been shown for lung
tumors.47 SCLC lines have the additional advantage of
natural growth as spheroids or ﬂoating cell aggregates,
and are enriched for stem cell populations.48
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Multistage Pathogenesis. Nonmalignant lung adjacent
to resected lung cancer is often used as a “normal
control.” There are problems with this concept: (1)
there is little histologically normal lung in heavy
smokers who are suffering from chronic inﬂammation
and chronic obstructive pulmonary disease (COPD); (2)
ﬁeld changes may be present throughout the lung from
widespread exposure to tobacco smoke and other
carcinogens, even in a histologically “normal” lung; and
(3) the respiratory epithelial cells represent a small
minority of the cells in peripheral lung. In an effort to
develop better control cells, our group and others have
immortalized respiratory cells from large and small
airways without the use of viral oncogenes.49 Such
cells from both sources have properties of basal stem
cells of the bronchi, which are believed to be the pro-
genitor cells of lung SCC. Sequential manipulations of
genes (both oncogenes and tumor suppressor genes)
involved in the pathogenesis of lung cancers results in
a model for multistage pathogenesis of lung cancers,
mainly SCC and large cell carcinomas.50 Inactivation of
STK11 (in combination with other oncogenic manipu-
lations) results in a wider range of morphologies,
including adenosquamous carcinomas.51
Mouse Avatars for Personalized Therapy Selection: A
Mighty Mouse? Until now, we have discussed the role of
preclinical models—but can they really lead to improved
patient management? One potential direct clinical appli-
cation from xenografts is the so-called mouse avatars26
(http://www.the-scientist.com/?articles.view/articleNo/
42470/title/My-Mighty-Mouse/): PDXs used for the se-
lection of personalized therapy. A commercial company is
currently offering to personalize oncology drug selection
using such a methodology. While of great theoretical in-
terest, problems include the long latent time until therapy
selection, the relatively high cost, and insufﬁcient data to
fully evaluate the usefulness of the method.
A CRISPR Application. The clustered regularly inter-
spersed short palindromic repeats (CRISPR)/Cas9 sys-
tem of RNA-guided genome editing is having a profound
effect on many aspects of genetics research.52 CRISPR
has applications in mouse models, including the gener-
ation of null, conditional, precisely mutated, reporter, or
tagged alleles in mice.53 There are already several CRSPR
applications to study mouse genomics and tumor
biology,52,54 and their use in lung cancer mouse models
will surely follow in the near future.
In conclusion, preclinical models have multiple spe-
ciﬁc and overlapping uses and limitations.1 Potential
applications include the preclinical development of novel
targeted therapies in genetically deﬁned tumors, anenhanced understanding of drug resistance and mecha-
nisms to bypass this, the identiﬁcation of potential bio-
markers and imaging techniques for early detection,
testing drugs for cancer prevention, mechanisms of in-
vasion and metastasis, and to determine the effects of
environmental factors on tumor progression.30
Cell lines and PDXs represent the vast spectrum and
heterogeneity of lung cancers. Cell lines in particular are
useful for studying biology, and are often used as the
ﬁrst screen for detection of conventional and targeted
therapies. They may also be used for the synthetic lethal
screen identiﬁcation of vulnerabilities in cancer cells.55
PDXs have the major advantage of having stromal cells
and a vascular system (although of murine origin). They
are often used as a secondary screen before moving
therapeutic targets to the clinic. They may also be used
for the selection of personalized medicine (“mouse ava-
tars”), although the lengthy lag time may mandate
administration of nonpersonalized therapy during this
period. The role of the tumor microenvironment and
selection of the ideal inoculation site may vary with the
application. In particular, does orthotopic trans-
plantation offer concrete beneﬁts over the more easily
administered and monitored subcutaneous route?
GEMM models are easily genetically modiﬁed and may
incorporate multiple genetic changes into a single model.
The GEMM models for lung cancer are not smoke-
induced, and therefore the genetic changes in the
resultant tumors lack the characteristic mutational sig-
natures of tobacco-associated malignancies. They are
highly suitable for studying tumor initiation and pro-
gression including metastases.30,32,56 Their responses to
targeted therapies may be dramatic. Despite these ad-
vances, clinical trials, especially of conventional thera-
pies selected by testing preclinical models, have often
yielded disappointing results. Much work remains to be
performed on how to make the preclinical models more
predictive of clinical response.
Despite their limitations, in vitro models remain the
single most important source of knowledge about the
nonclinical aspects of lung cancer and will likely remain
so into the foreseeable future. Additional or improved
recently developed approaches and methods may aid the
usefulness of the models and provide greater versatility.
Technical improvements have greatly aided the success
rate of generating models and the ability to rapidly
generate a wide variety of GEMMs of increasing molec-
ular complexity. In order to capture the diversity and
intratumor heterogeneity of human lung cancers, large
banks of each model, preferably fully characterized, must
be available to the scientiﬁc community. Because gener-
ation of such extensive, well characterized models is
beyond the scope of most individual laboratories, close
cooperation between investigators and sharing of pooled
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preclinical34 models. With the heightened interest in
PDXs,23,24 especially for the testing of conventional and
targeted therapies, it becomes important to establish
large banks of the different tumor types so as to capture
the genetic diversity and heterogeneity of human tumors
and the range of drug sensitivities. Cell line banks are
operated by several commercial and not for proﬁt orga-
nizations and by the originators of large collections.
Because of the cost and effort of establishing and
maintaining PDX banks, they are best performed by
consortiums that pool resources andmake them available
to the scientiﬁc public. One such effort is by the newly
established European EurOPDX initiative.25 We are un-
aware of a central bank for the distribution of GEMMs.
The major preclinical models for lung cancer each
have their individual strengths and weaknesses, and
each model has to be carefully evaluated for its suit-
ability for the proposed experimental approach.
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